| Today’s Big NewsNov 15, 2023 |
| By Angus Liu In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. |
|
|
|
By Nick Paul Taylor Gilead’s Kite is paying Arcellx $285 million to inject a SparX into its pursuit of BCMA. In return for the outlay, $200 million of which is being invested in Arcellx, Kite has secured rights to an early-phase BCMA CAR-T candidate and expanded its existing midphase cell therapy collaboration to cover lymphomas. |
By Conor Hale The nucleus of the case involves DNA sequencing patents developed by TwinStrand’s former CEO while he was a medical student at the University of Washington. |
By Max Bayer Organon CEO Kevin Ali says that while it wasn't involved in the recent women's health initiative announced by the White House, it plans to be moving forward. |
By Zoey Becker The CDMO reaffirmed its full year 2024 revenue guidance range of $4.3 billion to $4.5 billion, despite once high COVID revenue continuing to plunge. Now, Catalent is relying on contracts from Sarepta's DMD gene therapy and GLP-1 products. |
By Andrea Park The FDA has doled out its most serious classification to a recall of some 32 million of Cardinal Health's medical supplies. |
By Kevin Dunleavy CorMedix went through a lot to secure its FDA approval for DefenCath. There was a reorganization, a CEO change, an exit from Europe, two complete response letters and a switch of manufacturers and suppliers. And it took a novel pathway for the approval to finally come through on Wednesday. |
By Annalee Armstrong Regeneron is pretty good at making antibodies. It’s kind of its thing. But while the industry has gone crazy for antibody-drug conjugates, the company has stayed out of the limelight. |
By Conor Hale After winning an FDA clearance earlier this year for its image-guided radiation treatment for cancer, RefleXion Medical has raised $105 million to boost commercialization efforts as well as develop new applications for its approach. |
By Fraiser Kansteiner After reporting a sizable revenue decline for its BMS-parntered multiple myeloma cell therapy in 2023’s third quarter, 2seventy stands out as a prime example of the dangers of scaling up a process before suffering lower-than-expected demand, one group of analysts contends. |
By Annalee Armstrong Lenz Therapeutics is absorbing sickle-cell-focused Graphite Bio in a reverse merger that will see the combined company reemerge with a focus on vision loss and $225 million in cash on hand at close. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of "Podnosis," you'll hear from two journalists from the Fierce Healthcare team: Paige Minemyer, senior editor of Fierce Health Payer, and Dave Muoio, a staff writer for Fierce Healthcare. Together, they guide you through their key insights from the inaugural Fierce Health Payer Summit in Austin and dive into the latest earnings updates from the largest health plans and health systems. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape.
|
|
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
